COPD稳定期患者以噻托溴铵联合舒利迭治疗的效果分析  

Tiotropium bromide combined with seretide in treatment of COPD patients in stationary period

作　　者：赵丽格 闫佳强 李富东[1] 刘会彬[1] 王洛[1] 于康宁[1] Zhao Lige;Yan Jiaqiang;Li Fudong;Liu Huibin;Wang Luo;Yu Kangning(Department of Internal Medicine, Luoyang 202 Hospital, China Air-to-Air Missile Research Institute, Luoyang 471003, China)

机构地区：[1]中国空空导弹研究院洛阳二0二医院内科,洛阳471003

出　　处：《国际医药卫生导报》2018年第12期1849-1851,共3页International Medicine and Health Guidance News

摘　　要：目的对COPD稳定期患者以噻托溴铵联合舒利迭治疗的效果进行探究分析。方法将收治的COPD稳定期患者104例，随机分为参照组和观察组，各52例，参照组患者采用舒利迭治疗，观察组在上述基础上联用噻托溴铵治疗。两组治疗前后的呼吸困难评分、6MWT（6min步行试验）、血气指标、肺功能指标以及COPD急性发作率和不良反应发生情况比较。结果治疗前，两组呼吸困难评分、6MWT、血气指标和肺功能指标，差异无统计学意义（P〉0．05），经治疗后，上述指标改善情况观察组均显著优于参照组，差异有统计学意义（P〈0．05）；观察组COPD急性发作率明显低于参照组，差异有统计学意义（P〈0．05）。结论在COPD稳定期患者的治疗中采用噻托溴铵联合舒利迭治疗，可显著改善病患临床症状，有利于肺功能的提升，降低了COPD急性发作率，具有较高的推广应用价值。Objective To investigate the effect of tiotropium bromide combined with seretide in the treatment of COPD patients in stationary period. Methods 104 COPD patients in stationary period were divided into a control group and an observation group, 52 cases for each group. The control group were treated with seretide, and the observation group with seretide and tiotropium bromide. The dyspnea scores, 6MWT （6min walking test） before and after the treatment, blood gas index, pulmonary function index, and acute attack rate and adverse reaction of COPD were compared between these two groups. Results Before the treatment, there were no statistical differences in dyspnea score, 6MWT, blood gas index, and pulmonary function index between the two groups （P〉0.05）. After the treatment, the improvement of these indexes was significantly better in the observation group than in the control group （P〈0.05）. The acute attack rate of COPD was significantly lower in the observation group than in the control group （P〈0.05）. Conclusions In treatment of COPD patients at stationary period, Tiotropium Bromide combined with Seretide can significantly improve the clinical symptoms and lung function and reduce the acute attack rate of COPD, so it has high value of popularization and application.

关 键 词：慢性阻塞性肺疾病 噻托溴铵 舒利迭 效果 

分 类 号：R563.9[医药卫生—呼吸系统]